Nielsen Matthew E, Bastian Patrick J, Palapattu Ganesh S, Trock Bruce J, Schoenberg Mark P, Chan Theresa, Rogers Craig G
James Buchanan Brady Urological Institute, Johns Hopkins Hospital, Baltimore, Maryland 21287-2101, USA.
Urology. 2007 Dec;70(6):1091-5. doi: 10.1016/j.urology.2007.08.044.
The finding of bladder cancer invading the detrusor muscle on transurethral resection (TUR) is one of the clearest indications for radical cystectomy. To the extent that detrusor invasion is, in practical effect, a binary variable, the variety of outcomes after radical cystectomy in these patients belies the simplicity of this approach. In this context, we assessed bladder cancer recurrence-free survival among patients noted to have muscle-invasive urothelial carcinoma (transitional cell cancer [TCC]) on staging TUR subsequently found to have non-muscle-invasive TCC at radical cystectomy (downstaged).
The records of 248 consecutive patients who underwent radical cystectomy for TCC at a single academic institution from 1994 to 2002 were retrospectively reviewed. Of these patients, 112 (45%) had documented muscle-invasive disease by TUR and were clear of gross residual tumor on cystoscopy before radical cystectomy.
Of the 112 patients, 25 (22.3%) were downstaged to non-muscle-invasive disease (Stage pT1 or less) at cystectomy and 87 (77.7%) had persistent muscle-invasive disease (Stage pT2 or greater) at cystectomy. Recurrence occurred in 4 downstaged patients (16.0%) compared with 29 patients (33.3%) who were not downstaged (P = 0.094). Kaplan-Meier analysis demonstrated a statistically significant improvement in recurrence-free survival with downstaging (log-rank P = 0.008). Multivariate analysis demonstrated a threefold reduction in recurrence risk with tumor downstaging (hazard ratio 0.33, 95% confidence interval 0.10 to 1.12) that approached statistical significance (P = 0.075). Nodal status was the strongest predictor of RFS.
Downstaging from muscle-invasive TCC on TUR to non-muscle-invasive TCC at radical cystectomy can be associated with a reduced risk of recurrence even after adjusting for lymph node status and adjuvant chemotherapy.
经尿道切除术(TUR)发现膀胱癌侵犯逼尿肌是根治性膀胱切除术最明确的指征之一。实际上,逼尿肌侵犯是一个二元变量,但这些患者根治性膀胱切除术后的各种结果却表明这种方法并非如此简单。在此背景下,我们评估了在分期TUR时被诊断为肌层浸润性尿路上皮癌(移行细胞癌[TCC])、随后在根治性膀胱切除术中发现为非肌层浸润性TCC(分期降低)的患者的无癌复发生存期。
回顾性分析了1994年至2002年在单一学术机构接受TCC根治性膀胱切除术的248例连续患者的记录。在这些患者中,112例(45%)经TUR记录为肌层浸润性疾病,且在根治性膀胱切除术前行膀胱镜检查时无肉眼残留肿瘤。
在这112例患者中,25例(22.3%)在膀胱切除术中分期降低为非肌层浸润性疾病(pT1期或更低),87例(77.7%)在膀胱切除术中仍为持续性肌层浸润性疾病(pT2期或更高)。4例分期降低的患者(16.0%)出现复发,未分期降低的患者中有29例(33.3%)复发(P = 0.094)。Kaplan-Meier分析显示,分期降低使无癌复发生存期有统计学意义的改善(对数秩检验P = 0.008)。多变量分析显示,肿瘤分期降低使复发风险降低了三倍(风险比0.33,95%置信区间0.10至1.12),接近统计学意义(P = 0.075)。淋巴结状态是无癌复发生存期最强的预测因素。
即使在调整淋巴结状态和辅助化疗后,TUR时的肌层浸润性TCC在根治性膀胱切除术中分期降低为非肌层浸润性TCC仍可能与复发风险降低相关。